Last reviewed · How we verify
Bleomycin and Vincristine (BV)
Bleomycin and Vincristine is a combination chemotherapy regimen that damages DNA and disrupts microtubule formation to kill rapidly dividing cancer cells.
Bleomycin and Vincristine is a combination chemotherapy regimen that damages DNA and disrupts microtubule formation to kill rapidly dividing cancer cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Testicular cancer, Cervical cancer.
At a glance
| Generic name | Bleomycin and Vincristine (BV) |
|---|---|
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Drug class | Combination chemotherapy (bleomycin + vinca alkaloid) |
| Target | DNA (bleomycin); tubulin/microtubules (vincristine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bleomycin is a glycopeptide antibiotic that intercalates into DNA and causes strand breaks, leading to cell death. Vincristine is a vinca alkaloid that binds to tubulin and prevents microtubule assembly, arresting cells in metaphase. Together, they provide synergistic cytotoxic effects against malignant cells.
Approved indications
- Lymphomas (Hodgkin and non-Hodgkin)
- Testicular cancer
- Cervical cancer
- Other solid tumors and hematologic malignancies
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Pulmonary toxicity / pneumonitis
- Nausea and vomiting
- Peripheral neuropathy
- Alopecia
- Mucositis
- Fever
Key clinical trials
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: